Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …

Background The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …

Background Maintenance treatment of patients with advanced non-small-cell lung cancer
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …

Purpose: Gefitinib is a well known therapy for non-small-cell lung cancer (NSCLC). The
purpose of this study was to review clinical reports of gefitinib as maintenance therapy after …

LBA7511 Background: INFORM (a phase III, randomized, multicenter, parallel group study;
NCT00770588) investigated the efficacy, safety and tolerability of gefitinib (G) vs. placebo …

Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …

Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …